GlassScriptPhysician profile
Kayla L Ehrman
NPI 1316357494
$201,686.85
in general payments reported to CMS, 2019-2025
19 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18K · 2021: $27K · 2022: $26K · 2023: $37K · 2024: $42K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $108K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $2,396 · Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $108,012.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,700.00 |
| Travel and Lodging | $2,396.30 |
| Food and Beverage | $2,278.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $108,012.50 | 2023-2025 | |
| Csl Behring | $71,318.85 | 2020-2025 | Hizentra |
| Lilly USA, LLC | $21,062.24 | 2024-2025 | Kisunla |
| Eisai INC. | $671.26 | 2024-2025 | |
| Lundbeck LLC | $97.52 | 2024-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $96.72 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $67.38 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $58.21 | 2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $50.37 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $45.31 | 2024-2025 | |
| Abbvie INC. | $39.18 | 2024-2025 | |
| Ge Healthcare | $36.94 | 2025 | |
| C2n Diagnostics, LLC | $27.71 | 2025 | Precivityad2 |
| Abbott Laboratories | $20.70 | 2024 | Infinity |
| Supernus Pharmaceuticals, INC. | $18.25 | 2025 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $17.66 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.88 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $15.77 | 2024 | Hyqvia |
| Harmony Biosciences LLC | $14.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Ehrman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.